Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $460
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $455 to $460.
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $455 to $460.